Table 1.
Patient characteristics were evaluated using the sample size of all subjects meeting safety criteria, n = 144
| NMTRC009 patient characteristics | N = 144 |
|---|---|
| Enrollment age, years | |
| Mean (range) | 11.04 (1, 23) |
| Median | 11 |
| ≥ 10, n (%) | 82 (56.94%) |
| < 10, n (%) | 62 (43.06%) |
| Sex, n (%) | |
| Female | 62 (43.06%) |
| Male | 82 (56.94%) |
| Race/ethnicity, n (%) | |
| White | 93 (64.58%) |
| Black/African American | 10 (6.94%) |
| Asian | 5 (3.47%) |
| Hispanic | 13 (9.03%) |
| Others/unknown | 23 (15.97%) |
| Lansky status, n (%) | |
| ≥ 80 | 125 (86.81%) |
| < 80 | 19 (13.19%) |
| Previous relapse treatment lines, n (%) | |
| New diagnosis | 3 (2.08%) |
| 0 | 41 (28.47%) |
| 1 | 36 (25.00%) |
| 2 | 19 (13.19%) |
| ≥ 3 | 45 (31.25%) |
| Time from diagnosis to enrollment, years | |
| Mean (range) | 3.1 (0, 19) |
| Median | 2 |
| Tumor type, n (%) | |
| Neuroblastoma | 31 (21.53%) |
| CNS tumor | 41 (28.47%) |
| Ependymoma | 9 (6.25%) |
| Glioblastoma | 8 (5.55%) |
| Diffuse midline glioma | 4 (2.78%) |
| Other CNS tumors | 20 (13.89%) |
| Rare tumor | 72 (50.00%) |
| Rhabdomyosarcoma | 17 (11.81%) |
| Ewing sarcoma | 12 (8.33%) |
| Osteosarcoma | 10 (6.94-%) |
| Other rare tumors | 33 (22.92%) |